Twist Bioscience raises outlook as AI DNA demand builds profit focus

• Twist Biosciences (NasdaqGS:TWST) reported its 12th consecutive quarter of revenue growth.
• The company raised its full-year outlook, citing momentum in AI-powered DNA synthesis and expanded use of its platform.
• Management also reiterated its focus on improving profitability in parallel with business expansion.

Twist Bioscience is a provider of synthetic DNA and related tools, operating at the intersection of biotechnology and AI-driven research. Its platform supports customers in fields such as drug discovery, genomics, and data storage that rely heavily on accurate, high-throughput DNA synthesis. As AI tools become more commonplace in lab workflows, the company’s position in this niche market is gaining attention from both industry users and investors.

For investors keeping an eye on NasdaqGS:TWST, the combination of continued revenue growth, a higher full-year outlook, and a clear focus on profitability puts the business model into sharper focus. Key questions now center on how Twist can efficiently translate demand for AI-powered DNA synthesis into scale, improved margins, and a more mature financial profile over time.

Stay up to date with the most important news stories about Twist Bioscience by adding it to your watchlist or portfolio. Or explore our community and discover new perspectives on Twist Bioscience.

Why Twist Bioscience is a great value

Twist Bioscience’s 12th consecutive quarter of revenue growth, with first-quarter sales of USD 103.7 million (compared to USD 88.71 million a year ago) and full-year guidance raised from USD 435 million to USD 440 million, shows that customer demand for AI-enabled detection and DNA tools is reflected in the numbers. Q2 revenue guidance of USD 107 million to USD 108 million represents approximately 16% year-over-year growth at the midpoint, indicating continued traction even as the company still reported a net loss of USD 30.51 million, with only a slight improvement in underlying loss per share year-over-year.

How this earnings report fits into the Twist Bioscience story

For investors who view Twist as a scalable DNA synthesis platform, the quarter’s guidance hike and 17% year-over-year revenue growth could be interpreted as support for a more optimistic story about AI-powered drug discovery and protein solutions. At the same time, the continued loss and management’s goal to achieve adjusted EBITDA breakeven by the fourth quarter of fiscal 2026 speaks directly to a more cautious story focused on profitability timing, cost discipline, and competitive pressures from large tools companies such as Thermo Fisher Scientific, Illumina, and Agilent Technologies.

Focus on key risks and benefits

• Twelve consecutive quarters of revenue growth and a full-year outlook of approximately 16% growth at the midpoint suggest that Twist is using its AI-powered platform for discovery to capture customer attention.
• Investors will have a clearer baseline to track progress toward profitability as management reiterates its goal of achieving adjusted EBITDA breakeven by the second half of fiscal 2026.
• The company remains unprofitable, reporting a quarterly net loss of USD 30.51 million, but analysts note that profitability is a key risk over the next three years.
• Analysts also highlight customer concentration and competition from larger peers as continuing risks that could impact revenue stability and future profitability.

What to watch next

Looking forward, a key signal to watch is whether Twist can bring quarterly revenue closer to guidance, improve gross margins, and narrow losses while investing in AI-related opportunities and infrastructure. If you want to know more broadly how different investors think about these trade-offs, check out the community stories on the company’s dedicated page and compare the bull and bear cases to your own expectations.

This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.

Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email editorial-team@simplywallst.com.